Cleveland Clinic Abu Dhabi: A New Era of Cardiac Excellence

By HEOR Staff Writer

November 5, 2023

A Landmark Achievement in Healthcare

The Department of Health – Abu Dhabi (DoH) has declared Cleveland Clinic Abu Dhabi, a component of the M42 network, as a Centre of Excellence (CoE) for Adult Cardiac Surgery (ACS). This significant announcement is a testament to Abu Dhabi’s commitment to delivering world-class healthcare services to its community and reinforces its standing as a leading healthcare destination.

Centre of Excellence for Adult Cardiac Surgery: A New Standard in Cardiac Care

As an ACS CoE, Cleveland Clinic Abu Dhabi offers a comprehensive range of cardiac surgery and structural heart disease interventions. These services are provided by a team of highly experienced cardiologists and some of the world’s most reputable surgeons. The Clinic boasts dedicated cardiac surgery ICU facilities and cardiac operating rooms, supported by core services that include multidisciplinary cardiovascular medicine, interventional cardiology, electrophysiology, and a pioneering structural heart programme.

H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, emphasised the importance of the CoE programme in elevating healthcare outcomes and increasing competitiveness across the sector. She expressed delight at the announcement and looked forward to the continuous contributions from partners to enhance the healthcare sector’s excellence.

Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi and Managing Director and Group Chief Executive Officer of M42, highlighted the Clinic’s establishment as a regional and global benchmark for complex care. He reiterated their commitment to excellence and the vision of providing world-class complex care to patients in the UAE and across the region.

Reference url

Recent Posts

Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand

By João L. Carapinha

May 22, 2026

Portugal health spending 2025 hit a fresh peak as the country’s publicly funded National Health Service recorded its highest annual outlay on medicines, reaching €4.417 billion according to Infarmed data. This total, already net of industry rebates and contributions, was propelled chiefly by expa...
Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications

By HEOR Staff Writer

May 21, 2026

Substandard medicines in South Africa continue to infiltrate supply chains through informal markets, unlicensed outlets, and online platforms, leaving patients exposed to unregulated weight-loss injections amid stock shortages and high costs for approved options such as Ozempic. Comp...
First-in-Human Trials: Foundations and Market Implications in Health Economics
First-in-Human Trials mark the initial transition of a drug candidate from extensive preclinical research into human subjects, supplying the earliest clinical evidence on safety, pharmacokinetics, and pharmacodynamics to inform later development stages. These studies rely on a comprehensive found...